Year-end Sale % OFF 
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare severe central nervous system (CNS) opportunistic infection usually occurring in immunocompromised patients. Iatrogenic PML has been described in patients assuming treatment suppressing immune surveillance in CNS. Daratumumab is an anti-CD38 monoclonal antibody, used to treat Multiple Myeloma (MM), causing the destruction of suppressive cells and the increase of CD4+ helper and CD8+ cytotoxic T cells. Only two cases of PML on daratumumab has been reported in literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
